Credit Suisse Lowers Pear Therapeutics' Price Target to $9 from $11, Adjusts Guidance While Awaiting Reorganization Impact; Keeps Outperform Rating
Credit Suisse Lowers Pear Therapeutics' Price Target to $9 from $11, Adjusts Guidance While Awaiting Reorganization Impact; Keeps Outperform Rating
瑞士信贷将Pear Therapeutics的目标股价从11美元下调至9美元，在等待重组影响的同时调整了指导方针；维持跑赢大盘评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册